These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 29799981)

  • 1. Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging.
    Kim HJ; Park S; Cho H; Jang YK; San Lee J; Jang H; Kim Y; Kim KW; Ryu YH; Choi JY; Moon SH; Weiner MW; Jagust WJ; Rabinovici GD; DeCarli C; Lyoo CH; Na DL; Seo SW
    JAMA Neurol; 2018 Aug; 75(8):999-1007. PubMed ID: 29799981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Amyloid-β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease.
    Jang H; Kim HJ; Choe YS; Kim SJ; Park S; Kim Y; Kim KW; Lyoo CH; Cho H; Ryu YH; Choi JY; DeCarli C; Na DL; Seo SW;
    J Alzheimers Dis; 2020; 78(2):573-585. PubMed ID: 33016911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.
    Gomperts SN; Locascio JJ; Makaretz SJ; Schultz A; Caso C; Vasdev N; Sperling R; Growdon JH; Dickerson BC; Johnson K
    JAMA Neurol; 2016 Nov; 73(11):1334-1341. PubMed ID: 27654968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
    Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
    JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of an amyloid and tau classification system in subcortical vascular cognitive impairment patients.
    Jang H; Kim HJ; Park S; Park YH; Choe Y; Cho H; Lyoo CH; Yoon U; Lee JS; Kim Y; Kim SJ; Kim JP; Jung YH; Ryu YH; Choi JY; Moon SH; Seong JK; DeCarli C; Weiner MW; Lockhart SN; Cho SH; Na DL; Seo SW
    Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):292-303. PubMed ID: 31471715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct amyloid distribution patterns in amyloid positive subcortical vascular cognitive impairment.
    Jang H; Park JY; Jang YK; Kim HJ; Lee JS; Na DL; Noh Y; Lockhart SN; Seong JK; Seo SW
    Sci Rep; 2018 Nov; 8(1):16178. PubMed ID: 30385819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between Alzheimer's Disease and Cerebral Small Vessel Disease: A Review Focused on Neuroimaging Markers.
    Kim SE; Kim HJ; Jang H; Weiner MW; DeCarli C; Na DL; Seo SW
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebral small vessel disease and the risk of Alzheimer's disease: A systematic review.
    Liu Y; Braidy N; Poljak A; Chan DKY; Sachdev P
    Ageing Res Rev; 2018 Nov; 47():41-48. PubMed ID: 29898422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
    Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
    JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [
    Young CB; Landau SM; Harrison TM; Poston KL; Mormino EC;
    Neuroimage; 2021 Nov; 243():118553. PubMed ID: 34487825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain network alterations in individuals with and without mild cognitive impairment: parallel independent component analysis of AV1451 and AV45 positron emission tomography.
    Li Y; Yao Z; Yu Y; Zou Y; Fu Y; Hu B;
    BMC Psychiatry; 2019 Jun; 19(1):165. PubMed ID: 31159754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.
    Buckley RF; Mormino EC; Rabin JS; Hohman TJ; Landau S; Hanseeuw BJ; Jacobs HIL; Papp KV; Amariglio RE; Properzi MJ; Schultz AP; Kirn D; Scott MR; Hedden T; Farrell M; Price J; Chhatwal J; Rentz DM; Villemagne VL; Johnson KA; Sperling RA
    JAMA Neurol; 2019 May; 76(5):542-551. PubMed ID: 30715078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining iron-related off-target binding effects of
    Langley J; Bennett IJ; Hu XP;
    Eur J Neurosci; 2024 Jul; 60(1):3614-3628. PubMed ID: 38722153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Amyloid Positivity in Patients with Subcortical Vascular Cognitive Impairment.
    Moon H; Ham H; Yun J; Shin D; Lee EH; Kim HJ; Seo SW; Na DL; Jang H
    J Alzheimers Dis; 2024; 99(3):1117-1127. PubMed ID: 38788077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.